UTICA, N.Y. — Researchers at the Masonic Medical Research Institute (MMRI) in Utica will use a nearly $300,000 funding award for a study examining if there is a link between cardiac abnormalities and autism.
The American Heart Association chose MMRI for the Transformational Project Award, per a news release.
Maria Kontaridis, MMRI executive director, and Gordon Moe, professor of biomedical research and translational medicine at MMRI, will be working on the study for the next three years.
(Sponsored)
Why Now Is the Time To Start Planning for Your Company’s Business Succession
You’ve built a great business, and you love what you do. Retirement is a long way off, so why worry about how you’ll transition the ownership of your company down
Maximizing Tax Benefits for Energy-Efficient Buildings
The Inflation Reduction Act (IRA) of 2022 significantly enhanced the Section 179D deduction, making it even more valuable for businesses investing in energy-efficient commercial building property (EECBP) and energy-efficient commercial
Kontaridis and her co-investigator, Gulhan Ercan-Sencicek, an instructor at MMRI, will begin their project on Friday. Titled “The role of PTPN11 mutations in autism and heart pathogenesis,” it seeks to understand how mutations in the same gene differentially affect the normal processes of heart and brain development.
Kontaridis and Ercan-Sencicek will look at disease-causing changes in the PTPN11 gene, a nodal gene involved in critical signaling processes that regulate normal growth and differentiation of cells in multiple tissues, including brain and heart.
“We have identified two novel mutations that we think link autism with heart abnormalities in human patients,” Ercan-Sencicek said. “To understand the role of these mutations, we will reprogram somatic cells obtained from patients with these unique mutations and convert them into inducible pluripotent stem cells (iPSCs), cells that have the ability to differentiate into any tissue type of interest. For this project, we will differentiate these iPSCs into heart muscle cells and brain organoid cells to study the effects of PTPN11 mutations on heart disease and brain development. These results will help us to identify potential novel therapeutics that can be used to treat patients.”
